USFDA approves Vizimpro drug to treat Lung cancer
Vizimpro is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Banglore: Pfizer Inc informed that its drug to treat a rare form of lung cancer got approval from the U.S. Food and Drug Administration.
The drug, Vizimpro, will look to treat previously untreated patients with a form of metastatic non-small cell lung cancer. VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
The FDA had granted the drug Priority Review designation earlier this year. The status is given to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel)
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd